Three-month romosozumab followed by denosumab is noninferior to a 12-month course for total hip BMD gains in postmenopausal osteoporosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results